Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Short term Debt (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Short term Debt for 4 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 52.67% to $57.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.3 million through Dec 2025, up 52.67% year-over-year, with the annual reading at $57.3 million for FY2025, 52.67% up from the prior year.
  • Short term Debt hit $57.3 million in Q4 2025 for NewAmsterdam Pharma, up from $44.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $57.3 million in Q4 2025 to a low of $4.1 million in Q4 2022.
  • Historically, Short term Debt has averaged $27.6 million across 4 years, with a median of $23.5 million in 2024.
  • Biggest five-year swings in Short term Debt: skyrocketed 203.21% in 2023 and later dropped 28.85% in 2025.
  • Year by year, Short term Debt stood at $4.1 million in 2022, then surged by 203.21% to $12.6 million in 2023, then surged by 198.35% to $37.5 million in 2024, then skyrocketed by 52.67% to $57.3 million in 2025.
  • Business Quant data shows Short term Debt for NAMS at $57.3 million in Q4 2025, $44.4 million in Q3 2025, and $20.9 million in Q2 2025.